American College of Cardiology Meeting In Brief: Roche's mibefradil
Executive Summary
Roche's mibefradil: In the dose-ranging Mibefradil Ischemia Suppression Trial (MIST) in patients with coronary artery disease and angina, mibefradil significantly increased the time to onset of angina in exercising patients, Dan Tzivoni, MD, Shaare Zedek Medical Center, Jerusalem, reported March 26. Mibefradil additionally increased exercise duration by 11%-24% at different doses, reduced the number of ischemic episodes by 65%-74%, reduced the duration of ischemia by 64%-75% and reduced maximum ST depressions by 50%-62%. Mibefradil is in Phase III in the U.S...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth